It’s RFK Jr.’s FDA now

Taking stock of the drug industry, from the lab to the medicine chest

March 31, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

SUSAN WALSH/POOL/AFP via Getty Images STAT+ | It's RFK Jr.'s FDA now The forced exit of a senior official seems to signal that changes rippling through RFK Jr.'s HHS Department will fully reach the FDA. By Matthew Herper STAT+ | FDA's 'key man' Peter Marks is out. Biotech investors will now deal with the consequences For biotech investors, Peter Marks' ouster from FDA comes at a time when the sector is suffering through a years-long public markets slump.  By Adam Feuerstein Down to their heart cells, women and men have cardiovascular differences that matter At at time when research into women's health is an outlawed DEI casualty, a look at heart disease in women shows the importance of studying sex differences. By Elizabeth Cooney

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser